

Pharmacy Benefact

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS

Number 582 • February 2016

Temporary benefit added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Apo-Clobazam 10 mg Tablet (DIN 02244638) manufactured by Apotex Inc. and Novo-Clobazam 10 mg Tablet (DIN 02238334) manufactured by Teva Canada Limited, Frisium 10 mg Tablet (DIN 02221799) manufactured by Lundbeck Inc. will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of February 2, 2016, all claims for Frisium 10 mg Tablet (DIN 02221799) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at <https://www.ab.bluecross.ca/providers/pharmacy-home.html>.

If this situation continues to be a long-term matter, then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)
FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit <https://www.ab.bluecross.ca/providers/pharmacy-home.php>



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.582 2016/02

